Products
Pre-Made Filgrastim Biosimilar, Recombinant Protein targeting CSF3R: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-852
Pre-Made Filgrastim Biosimilar, Recombinant Protein targeting CSF3R: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Filgrastim is a recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-852-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-852-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-852-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-852-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Filgrastim Biosimilar, Recombinant Protein targeting CSF3R: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 |
| INN Name | Filgrastim |
| Target | CSF3R/G-CSF-R |
| Format | Recombinant Protein |
| Derivation | 0 |
| Species Reactivity | human |
| CH1 Isotype | CSF3 (colony stimulating factor 3, GCSF, granulocyte colony-stimulating factor, G-CSF) |
| VD LC | CSF3 (colony stimulating factor 3, GCSF, granulocyte colony-stimulating factor, G-CSF) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Amgen (Thousand Oaks CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
